Combined 99mTc-ECD SPECT and neuropsychological s conversion to AD

Citation Report

#	ARTICLE	IF	CITATIONS
2	The neuroimaging approach to the assessment of mild cognitive impairment. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 745-748.	3.3	3
4	Regional cerebral blood flow reductions, heart failure and Alzheimer's disease. Neurological Research, 2006, 28, 579-587.	0.6	42
5	How do heart disease and stroke become risk factors for Alzheimer's disease?. Neurological Research, 2006, 28, 637-644.	0.6	125
6	Role of Neuroimaging in Alzheimer's Disease, with Emphasis on Brain Perfusion SPECT. Journal of Nuclear Medicine, 2007, 48, 1289-1300.	2.8	186
7	The proteasomal subunit S6 ATPase is a novel synphilinâ€‘1 interacting proteinâ€"implications for Parkinson's disease. FASEB Journal, 2007, 21, 1759-1767.	0.2	48
8	Diagnostic Value of Event-Related Evoked Potentials N200 and P300 Subcomponents in Early Diagnosis of Alzheimerâ€™s Disease and Mild Cognitive Impairment. Journal of Clinical Neurophysiology, 2007, 24, 405-412.	0.9	113
9	Imaging markers of mild cognitive impairment: Multivariate analysis of CBF SPECT. Neurobiology of Aging, 2007, 28, 1062-1069.	1.5	63
11	Greater Depression Severity in Elderly Patients With Memory Complaints Is Associated With Decreased Left Temporal-Parietal Dominance Indicated by Dynamic Susceptibility Contrast Magnetic Resonance Imaging Cerebral Blood Volume Measures. American Journal of Geriatric Psychiatry, 2007, 15, 604-610.	0.6	7
12	Diagnosing dementia in rural New South Wales. Australian Journal of Rural Health, 2007, 15, 183-188.	0.7	6
13	Permanent, bilateral common carotid artery occlusion in the rat: A model for chronic cerebral hypoperfusion-related neurodegenerative diseases. Brain Research Reviews, 2007, 54, 162-180.	9.1	606
14	Identifying functional imaging markers of mild cognitive impairment in early Alzheimerâ€™s and Parkinsonâ€™s disease using multivariate analysis. Clinical Neuroscience Research, 2007, 6, 367-373.	0.8	11
15	Pre-treatment and post-treatment with Î±-tocopherol attenuates hippocampal neuronal damage in experimental cerebral hypoperfusion. European Journal of Pharmacology, 2007, 571, 120-128.	1.7	43
16	Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDSâ€"ADRDA criteria. Lancet Neurology, The, 2007, 6, 734-746.	4.9	3,755
17	Cerebral perfusion correlates of conversion to Alzheimer's disease in amnestic mild cognitive impairment. Journal of Neurology, 2007, 254, 1698-1707.	1.8	81
18	Prevention of progression to dementia in the elderly: Rationale and proposal for a health-promoting memory consultation (an IANA task force). Journal of Nutrition, Health and Aging, 2008, 12, 520-529.	1.5	23
19	Brain SPECT in subtypes of mild cognitive impairment. Journal of Neurology, 2008, 255, 1344-1353.	1.8	54
20	Functional imaging of cognition in Alzheimer's disease using positron emission tomography. Neuropsychologia, 2008, 46, 1613-1623.	0.7	36
21	Feature Extraction and Strategy of Analyzing Structural Neuroimaging in Dementia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 75-86.	1.0	1

#	Article	IF	Citations
22	Cube Copying Test in Combination with rCBF or CSF Aβ$_{42}$ Predicts Development of Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2008, 25, 544-552.	0.7	20
23	Amnestic Mild Cognitive Impairment: Structural MR Imaging Findings Predictive of Conversion to Alzheimer Disease. American Journal of Neuroradiology, 2008, 29, 944-949.	1.2	162
24	Chapter 4 Functional neuroimaging of cognition. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 88, 61-111.	1.0	14
25	The logopenic/phonological variant of primary progressive aphasia. Neurology, 2008, 71, 1227-1234.	1.5	602
26	Basal Forebrain and Memory. , 2008, , 281-301.		4
27	Theoretical analysis of full-ring multi-pinhole brain SPECT. Physics in Medicine and Biology, 2009, 54, 6593-6610.	1.6	55
28	Fluorodeoxyglucose–Positron-Emission Tomography, Single-Photon Emission Tomography, and Structural MR Imaging for Prediction of Rapid Conversion to Alzheimer Disease in Patients with Mild Cognitive Impairment: A Meta-Analysis. American Journal of Neuroradiology, 2009, 30, 404-410.	1.2	178
29	Biomarkers of Alzheimer's disease. Neurobiology of Disease, 2009, 35, 128-140.	2.1	175
30	Principal component analysis in mild and moderate Alzheimer's disease – A novel approach to clinical diagnosis. Psychiatry Research - Neuroimaging, 2009, 173, 8-14.	0.9	35
31	Differential automatic diagnosis between Alzheimer's disease and frontotemporal dementia based on perfusion SPECT images. Artificial Intelligence in Medicine, 2009, 47, 147-158.	3.8	43
32	A Grid-based SPM service (GriSPM) for SPECT and PET neurological studies. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1193-1195.	3.3	4
33	Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease. Neurobiology of Aging, 2009, 30, 165-173.	1.5	69
34	Carotid Artery Ultrasound and Echocardiography Testing to Lower the Prevalence of Alzheimer's Disease. Journal of Stroke and Cerebrovascular Diseases, 2009, 18, 319-328.	0.7	30
37	Quantitative evaluation of Alzheimer's disease. Expert Review of Medical Devices, 2009, 6, 569-588.	1.4	14
38	SPECT Predictors of Cognitive Decline and Alzheimer's Disease in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2009, 17, 761-772.	1.2	42
39	ASL Perfusion MRI Predicts Cognitive Decline and Conversion From MCI to Dementia. Alzheimer Disease and Associated Disorders, 2010, 24, 19-27.	0.6	212
40	Grey and White Matter Changes at Different Stages of Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 19, 147-159.	1.2	135
41	Neuroimaging Through the Course of Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 19, 273-290.	1.2	19

#	ARTICLE	IF	CITATIONS
42	SPECT imaging of GABAA/benzodiazepine receptors and cerebral perfusion in mild cognitive impairment. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1156-1163.	3.3	16
43	Changes in pro-oxidant and antioxidant enzyme levels during cerebral hypoperfusion in rats. Brain Research, 2010, 1321, 13-19.	1.1	30
44	The California Verbal Learning Test and other standard clinical neuropsychological tests to predict conversion from mild memory impairment to dementia. Journal of Clinical and Experimental Neuropsychology, 2010, 32, 164-173.	0.8	45
46	99mTc Hexamethyl-Propylene-Aminoxime Single-Photon Emission Computed Tomography Prediction of Conversion From Mild Cognitive Impairment to Alzheimer Disease. American Journal of Geriatric Psychiatry, 2010, 18, 959-972.	0.6	28
47	Imaging and biomarkers for Alzheimer's disease. Maturitas, 2010, 65, 138-142.	1.0	12
48	Do CSF biomarkers help clinicians predict the progression of mild cognitive impairment to dementia?. Practical Neurology, 2010, 10, 202-207.	0.5	20
49	Association between syncope and cognitive impairment. Aging Health, 2011, 7, 143-153.	0.3	1
50	Brain perfusion SPECT with an automated quantitative tool can identify prodromal Alzheimer's disease among patients with mild cognitive impairment. Neurobiology of Aging, 2011, 32, 15-23.	1.5	80
51	The Clinical Use of SPECT and PET Molecular Imaging in Alzheimer's Disease. , 2011, , .		3
52	Study of Degradation Products and Degradation Pathways of ECD and Its Drug Product, ECD Kit. , 2011, , .		0
53	Impaired Visual Recognition Memory in Amnestic Mild Cognitive Impairment is Associated with Mesiotemporal Metabolic Changes on Magnetic Resonance Spectroscopic Imaging. Journal of Alzheimer's Disease, 2011, 22, 1269-1279.	1.2	28
54	Which Memory System is Impaired First in Alzheimer's Disease?. Journal of Alzheimer's Disease, 2011, 27, 11-22.	1.2	114
55	Grid-distributed Statistical Parametric Mapping of SPECT and PET Neuroimages. Neuroinformatics, 2011, 9, 85-90.	1.5	1
56	Asymmetric Cerebral Blood Flow in Patients with Mild Cognitive Impairment: Possible Relationship to Further Cognitive Deterioration. Dementia and Geriatric Cognitive Disorders Extra, 2011, 1, 228-236.	0.6	11
57	Regional brain atrophy and functional disconnection across Alzheimer's disease evolution. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 58-66.	0.9	233
58	Direct Determination of ECD in ECD Kit: A Solid Sample Quantitation Method for Active Pharmaceutical Ingredient in Drug Product. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-7.	3.0	3
59	Optimizing the Diagnosis of Early Alzheimer's Disease in Mild Cognitive Impairment Subjects. Journal of Alzheimer's Disease, 2012, 32, 969-979.	1.2	32
60	Significant correlation between cerebral hypoperfusion and neuropsychological assessment scores of patients with mild cognitive impairment. Nuclear Medicine Communications, 2012, 33, 848-858.	0.5	1

#	ARTICLE	IF	CITATIONS
61	The diagnosis and evaluation of dementia and mild cognitive impairment with emphasis on SPECT perfusion neuroimaging. CNS Spectrums, 2012, 17, 176-206.	0.7	28
62	Regional cerebral blood flow differences in patients with mild cognitive impairment between those who did and did not develop Alzheimer's disease. Psychiatry Research - Neuroimaging, 2012, 203, 201-206.	0.9	37
64	Parasympathetic autonomic dysfunction is common in mild cognitive impairment. Neurobiology of Aging, 2012, 33, 2324-2333.	1.5	86
65	Impaired memory and executive function associated with decreased medial temporal and prefrontal blood flow in Clinical Dementia Rating 0.5 status: the Osakiâ€Tajiri project. Psychogeriatrics, 2012, 12, 27-33.	0.6	15
66	Correlation between neuropsychological tests and hypoperfusion in MCI patients: anatomical labeling using xjView and Talairach Daemon Software. Annals of Nuclear Medicine, 2012, 26, 656-664.	1.2	22
67	Anatomical and Functional Deficits in Patients with Amnestic Mild Cognitive Impairment. PLoS ONE, 2012, 7, e28664.	1.1	75
68	A Two-Year Follow-Up of Cognitive Deficits and Brain Perfusion in Mild Cognitive Impairment and Mild Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 30, 109-120.	1.2	59
69	Monte Carlo feature selection and rule-based models to predict Alzheimerâ€™s disease in mild cognitive impairment. Journal of Neural Transmission, 2012, 119, 821-831.	1.4	13
70	Chrysin improves cognitive deficits and brain damage induced by chronic cerebral hypoperfusion in rats. European Journal of Pharmacology, 2012, 680, 41-48.	1.7	108
71	Parietal cortex matters in Alzheimer's disease: An overview of structural, functional and metabolic findings. Neuroscience and Biobehavioral Reviews, 2012, 36, 297-309.	2.9	203
72	The early contribution of cerebrovascular factors to the pathogenesis of Alzheimerâ€™s disease. European Journal of Neuroscience, 2012, 35, 1917-1937.	1.2	77
73	Processing of the Platelet Amyloid Precursor Protein in the Mild Cognitive Impairment (MCI). Neurochemical Research, 2013, 38, 1415-1423.	1.6	22
74	Neurotoxic Saboteurs: Straws that Break the Hippoâ€™s (Hippocampus) Back Drive Cognitive Impairment and Alzheimerâ€™s Disease. Neurotoxicity Research, 2013, 24, 407-459.	1.3	47
75	Emerging Biomarkers in Cognition. Clinics in Geriatric Medicine, 2013, 29, 809-828.	1.0	13
76	Neuropsychological Predictors of Conversion from Mild Cognitive Impairment to Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 38, 481-495.	1.2	150
77	Prediction of outcomes in MCI with 123I-IMP-CBF SPECT: a multicenter prospective cohort study. Annals of Nuclear Medicine, 2013, 27, 898-906.	1.2	29
78	Effects of mild chronic cerebral hypoperfusion and early amyloid pathology on spatial learning and the cellular innate immune response in mice. Neurobiology of Aging, 2013, 34, 679-693.	1.5	44
79	Synapse Stability in the Precuneus Early in the Progression of Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 35, 599-609.	1.2	50

#	ARTICLE	IF	CITATIONS
80	Evoked Potentials and Neuropsychological Tests Validate Positron Emission Topography (PET) Brain Metabolism in Cognitively Impaired Patients. PLoS ONE, 2013, 8, e55398.	1.1	11
81	Biomarkers of Alzheimerâ€™s disease. , 2014, , 801-815.		0
82	Cerebral Blood Flow Measured by Arterial Spin Labeling MRI as a Preclinical Marker of Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 42, S411-S419.	1.2	165
83	Pathophysiological rat model of vascular dementia: Magnetic resonance spectroscopy, microimaging and behavioral study. Brain Research, 2014, 1568, 10-20.	1.1	5
84	Neuroimaging in dementia. Maturitas, 2014, 79, 202-208.	1.0	21
85	Global brain hypoperfusion and oxygenation in amnestic mild cognitive impairment. Alzheimer's and Dementia, 2014, 10, 162-170.	0.4	62
87	Early neuropsychological detection of Alzheimer's disease. European Journal of Clinical Nutrition, 2014, 68, 1192-1199.	1.3	59
88	Usefulness of an Integrated Analysis of Different Memory Tasks to Predict the Progression from Mild Cognitive Impairment to Alzheimerâ€™s Disease: The Episodic Memory Score (EMS). Journal of Alzheimer's Disease, 2016, 50, 61-70.	1.2	18
89	Correlation of Tc-99Âm ethyl cysteinate dimer single-photon emission computed tomography and clinical presentations in patients with low cobalamin status. BMC Neurology, 2015, 15, 251.	0.8	7
90	Prolonged In Vivo Retention of a Cathepsin D Targeted Optical Contrast Agent in a Mouse Model of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 48, 73-87.	1.2	10
91	Neuropsychological tests for predicting cognitive decline in older adults. Neurodegenerative Disease Management, 2015, 5, 191-201.	1.2	15
92	Advances in CNS Imaging Agents: Focus on PET and SPECT Tracers in Experimental and Clinical Use. CNS Drugs, 2015, 29, 313-330.	2.7	14
93	Olfactory dysfunction: its early temporal relationship and neural correlates in the pathogenesis of Alzheimerâ€™s disease. Journal of Neural Transmission, 2015, 122, 1475-1497.	1.4	52
94	Domain Transfer Learning for MCI Conversion Prediction. IEEE Transactions on Biomedical Engineering, 2015, 62, 1805-1817.	2.5	148
95	Alterations in Rapid Eye Movement Sleep Parameters Predict for Subsequent Progression from Mild Cognitive Impairment to Alzheimerâ€™s Disease. , 2016, 06, .		3
96	Chronic cerebral hypoperfusion enhances Tau hyperphosphorylation and reduces autophagy in Alzheimerâ€™s disease mice. Scientific Reports, 2016, 6, 23964.	1.6	82
97	Longitudinal Changes in Functional Brain Connectivity Predicts Conversion to Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 51, 377-389.	1.2	51
98	Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimerâ€™s disease: a systematic review. BMC Geriatrics, 2016, 16, 104.	1.1	59

#	ARTICLE	IF	CITATIONS
99	Tc-99m-ECD SPECT as the measure for therapeutic response in patients with cobalamin deficiency. Medicine (United States), 2016, 95, e4851.	0.4	3
100	Chronic Cerebral Hypoperfusion Induced Synaptic Proteome Changes in the rat Cerebral Cortex. Molecular Neurobiology, 2018, 55, 4253-4266.	1.9	19
101	Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. Nature Reviews Neuroscience, 2017, 18, 419-434.	4.9	842
102	Different deficit patterns on word lists and short stories predict conversion to Alzheimer's disease in patients with amnestic mild cognitive impairment. Journal of Neurology, 2017, 264, 2258-2267.	1.8	21
103	The evaluation of brain perfusion SPECT using an easy Z-score imaging system in the mild cognitive impairment subjects with brain amyloid-Î² deposition. Clinical Neurology and Neurosurgery, 2017, 160, 111-115.	0.6	11
104	EFFECTS OF OMEGA-3 FATTY ACIDS ON RESTING CEREBRAL PERFUSION IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT: A RANDOMIZED CONTROLLED TRIAL. journal of prevention of Alzheimer's disease, The, 2018, 5, 1-5.	1.5	12
105	Prediction of Cognitive Decline from White Matter Hyperintensity and Single-Photon Emission Computed Tomography in Alzheimer's Disease. Frontiers in Neurology, 2017, 8, 408.	1.1	11
106	Inferior Parietal Cortex Hypoperfusion is the Most Specific Imaging Marker for AD Patients With Positive CSF Biomarker Assays in a Memory Clinic in France. Alzheimer Disease and Associated Disorders, 2018, 32, 89-93.	0.6	2
107	Predicting progression of amnesic MCI: The integration of episodic memory impairment with perfusion SPECT. Psychiatry Research - Neuroimaging, 2018, 271, 43-49.	0.9	15
108	A longitudinal characterization of perfusion in the aging brain and associations with cognition and neural structure. Human Brain Mapping, 2019, 40, 3522-3533.	1.9	47
109	Predicting progression to Alzheimer's disease in subjects with amnestic mild cognitive impairment using performance on recall and recognition tests. Journal of Neurology, 2019, 266, 102-111.	1.8	44
110	Non-invasive imaging modalities to study neurodegenerative diseases of aging brain. Journal of Chemical Neuroanatomy, 2019, 95, 54-69.	1.0	10
111	Roles of tau pathology in the locus coeruleus (LC) in age-associated pathophysiology and Alzheimer's disease pathogenesis: Potential strategies to protect the LC against aging. Brain Research, 2019, 1702, 17-28.	1.1	54
112	Associations between cerebral blood flow and structural and functional brain imaging measures in individuals with neuropsychologically defined mild cognitive impairment. Neurobiology of Aging, 2020, 86, 64-74.	1.5	42
113	Utility of Easy <i>Z</i>-Score Imaging System-Assisted SPECT in Detecting Onset Age-Dependent Decreases in Cerebral Blood Flow in the Posterior Cingulate Cortex, Precuneus, and Parietal Lobe in Alzheimer's Disease with Amyloid Accumulation. Dementia and Geriatric Cognitive Disorders Extra, 2020, 10, 63-68.	0.6	9
114	Spect-neuropsychology correlations in very mild Alzheimer's disease and amnesic mild cognitive impairment. Archives of Gerontology and Geriatrics, 2020, 89, 104085.	1.4	1
115	Comparison of Alzheimer's disease patients and healthy controls in the easy Z-score imaging system with differential image reconstruction methods using SPECT/CT: verification using normal database of our institution. Annals of Nuclear Medicine, 2021, 35, 307-313.	1.2	1
116	Cerebral Blood Flow Predicts Conversion of Mild Cognitive Impairment into Alzheimer's Disease and Cognitive Decline: An Arterial Spin Labeling Follow-up Study. Journal of Alzheimer's Disease, 2021, 82, 293-305.	1.2	26

#	ARTICLE	IF	CITATIONS
117	Involvement of cerebrovascular abnormalities in the pathogenesis and progression of Alzheimerâ€™s disease: an adrenergic approach. Aging, 2021, 13, 21791-21806.	1.4	9
118	Neuroimaging Findings in Mild Cognitive Impairment. , 2014, , 271-307.		2
119	Der Berliner-Apraxie-Test fÃ¼r ideomotorische und ideatorische Apraxie. Zeitschrift FÃ¼r Neuropsychologie = Journal of Neuropsychology, 2007, 18, 193-206.	0.2	8
120	Performance on neuropsychological assessment and progression to dementia: A meta-analysis.. Psychology and Aging, 2019, 34, 954-977.	1.4	22
121	Translational NeuroImaging of the CNS: Novel Pathways to Drug Development. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2009, 9, 302-313.	3.4	20
122	Is there Still a Place for Perfusion SPECT in the Diagnosis of Dementia?. The Open Nuclear Medicine Journal, 2010, 2, 40-45.	0.2	3
124	Absolute SPECT/CT quantification of cerebral uptake of 99mTc-HMPAO for patients with neurocognitive disorders. Nuklearmedizin - NuclearMedicine, 2016, 55, 158-165.	0.3	5
126	Regional cerebral perfusion in patients with amnestic mild cognitive impairment: effect of cerebral small vessel disease. Annals of Nuclear Medicine, 2021, , 1.	1.2	0
127	Role of Imaging Techniques in Discerning Neurobehavioral Changes in Ischemic, Neurodegenerative and Demyelinating Disorders. , 2009, , 17-54.		0
128	Genetics: Facts and Perspectives . . . . and Andrea Ginestroni. , 2016, , 127-154.		0
129	HMPAO-SPECT Can Discriminate between Patients with Subjective Cognitive Complaints with and without Cognitive Deficits and those with Mild Cognitive Impairment. Current Alzheimer Research, 2019, 16, 843-851.	0.7	1
130	Neuroimaging Findings in Mild Cognitive Impairment. , 2021, , 367-425.		1
132	Whole-body vibration exercise and training increase regional CBF in mild cognitive impairment with enhanced cognitive function. Annals of Nuclear Medicine, 2022, 36, 82-94.	1.2	9
133	Prediction and Modeling of Neuropsychological Scores in Alzheimerâ€™s Disease Using Multimodal Neuroimaging Data and Artificial Neural Networks. Frontiers in Computational Neuroscience, 2021, 15, 769982.	1.2	9
134	The Legacy of the TTASAAN Reportâ€"Premature Conclusions and Forgotten Promises: A Review of Policy and Practice Part I. Frontiers in Neurology, 2021, 12, 749579.	1.1	4
136	Altered Spontaneous Brain Activity in Patients With Diabetic Osteoporosis Using Regional Homogeneity: A Resting-State Functional Magnetic Resonance Imaging Study. Frontiers in Aging Neuroscience, 2022, 14, .	1.7	2
137	Patterns of structure-function association in normal aging and in Alzheimer's disease: Screening for mild cognitive impairment and dementia with ML regression and classification models. Frontiers in Aging Neuroscience, 0, 14, .	1.7	4